Darren Gitelman, MD
Behavioral Neurology & Neuropsychiatry · Park Ridge, ILNPI 1164530804
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,971 of the $63,457 with a category attached, or 72.4%. 10 manufacturers reported payments, led by Eli Lilly at 48.5% of the total. Reporting peaked in 2023 at $40,706 and has fallen 93.6% since, to $2,609 in 2025.
Across 63 payments — averaging $1007.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$31K
- Eisai Inc.$16K
- AbbVie$5K
- Biogen$4K
- Lilly USA, LLC$4K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $3K from 4 others
Across 193 payments — averaging $17,759 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Biogen$912K
- Eisai Inc.$733K
- AbbVie$376K
- E.r. Squibb & Sons, L.L.C.$288K
- Genentech, Inc.$27K
What the payments were for
- Consulting fees$45,97172%
- Speaking & faculty fees$3,3905%
- Travel & lodging$12,70120%
- Food & beverage$1,2902%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 22 | $30,772 |
| Eisai Inc. | 10 | $15,746 |
| AbbVie | 12 | $5,301 |
| Biogen | 7 | $3,549 |
| Lilly USA, LLC | 2 | $3,544 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,019 |
| Novo Nordisk | 3 | $1,500 |
| Merck | 1 | $800 |
| Genentech USA, Inc. | 1 | $150 |
| Genentech, Inc. | 2 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few behavioral neurology & neuropsychiatry providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 271 | $23,516 |
| RexultiBrexpiprazole | 13 | $22,613 |
| Rivastigmine | 59 | $14,842 |
| Memantine Hcl | 407 | $13,151 |
| Donepezil Hcl | 357 | $4,806 |
| Escitalopram Oxalate | 178 | $2,001 |
| Quetiapine Fumarate | 76 | $1,358 |
| Memantine Hcl ErMemantine Hcl | 19 | $1,209 |
| Mirtazapine | 24 | $1,202 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 45 | $1,075 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $1,007 |
| RivastigmineRivastigmine Tartrate | 14 | $906 |
| Bupropion XlBupropion Hcl | 19 | $790 |
| Trazodone Hcl | 76 | $569 |
| Sertraline Hcl | 57 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $3,544 | $26627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in Park Ridge
- Allison LapinsChicago$1K
- Busole MassunkenChicago$1K
- Arun RaviChicago$280
- Violeta SpasovaChicago$272
- Amy CorcoranChicago$53
- Shoaib MemonChicago$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.